{"id":6124,"date":"2021-09-16T00:01:10","date_gmt":"2021-09-16T00:01:10","guid":{"rendered":"https:\/\/bmj-chicken.bmj.com\/thebmj\/the-bmj-article\/raising-the-bar-for-using-surrogate-endpoints-in-drug-regulation-and-health-technology-assessment\/"},"modified":"2021-09-20T15:16:03","modified_gmt":"2021-09-20T15:16:03","slug":"raising-the-bar-for-using-surrogate-endpoints-in-drug-regulation-and-health-technology-assessment","status":"publish","type":"the-bmj-article","link":"https:\/\/bmj-chicken.bmj.com\/thebmj\/the-bmj-article\/raising-the-bar-for-using-surrogate-endpoints-in-drug-regulation-and-health-technology-assessment\/","title":{"rendered":"Raising the bar for using surrogate endpoints in drug regulation and health technology assessment"},"featured_media":0,"template":"","categories":[],"tags":[],"content_type":[22],"editorial_panel":[],"channel_page":[41],"class_list":["post-6124","the-bmj-article","type-the-bmj-article","status-publish","hentry","article-type-analysis","channel-page-comment"],"aioseo_notices":[],"meta_box":{"the_bmj_article-url":"\/content\/374\/bmj.n2191","the_bmj_article-description":"Surrogate endpoints should be used only as a last resort in drug trials, argue these authors ","the_bmj_article-the_bmj_article_image":[{"width":150,"height":150,"file":"2021\/09\/scientist_wearing_a_face_mask_working_in_a_laboratory.jpg","sizes":{"medium":{"file":"scientist_wearing_a_face_mask_working_in_a_laboratory-300x194.jpg","width":300,"height":194,"mime-type":"image\/jpeg","url":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-content\/uploads\/sites\/4\/2021\/09\/scientist_wearing_a_face_mask_working_in_a_laboratory-300x194.jpg"},"thumbnail":{"file":"scientist_wearing_a_face_mask_working_in_a_laboratory-150x150.jpg","width":150,"height":150,"mime-type":"image\/jpeg","url":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-content\/uploads\/sites\/4\/2021\/09\/scientist_wearing_a_face_mask_working_in_a_laboratory-150x150.jpg"}},"image_meta":{"aperture":"0","credit":"GORODENKOFF PRODUCTIONS\/SCIENCE","camera":"","caption":"Scientist wearing a face mask working in a laboratory.","created_timestamp":"0","copyright":"GORODENKOFF PRODUCTIONS\/SCIENCE PHOTO LIBRARY","focal_length":"0","iso":"0","shutter_speed":"0","title":"Scientist wearing a face mask working in a laboratory","orientation":"1","keywords":["laboratory","research","scientist","development","medical","medicine","test","tube","sample","pipette","protective","face","mask","computer","male","biotechnology","chemistry","pharmaceutical","technology","test","clinic","researching","biology","researcher","person","experiment","equipment","analysing","analysis","pharmacology","working","screen","drugs","one","person","lab","chemical","technological","biological","analyzing","pharmacological"]},"ID":"6122","name":"scientist_wearing_a_face_mask_working_in_a_laboratory.jpg","path":"\/dom34810\/wp-content\/uploads\/sites\/4\/2021\/09\/scientist_wearing_a_face_mask_working_in_a_laboratory.jpg","url":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-content\/uploads\/sites\/4\/2021\/09\/scientist_wearing_a_face_mask_working_in_a_laboratory-150x150.jpg","full_url":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-content\/uploads\/sites\/4\/2021\/09\/scientist_wearing_a_face_mask_working_in_a_laboratory.jpg","title":"Scientist wearing a face mask working in a laboratory","caption":"Scientist wearing a face mask working in a laboratory.","description":"","alt":"scientist","srcset":false}],"the_bmj_article-related_articles":[{"article_type":"Feature","related_article_title":"Should regulatory authorities approve drugs based on surrogate endpoints?","related_article_url":"https:\/\/www.bmj.com\/content\/374\/bmj.n2059"},{"article_type":"Opinion","related_article_title":"Surrogate endpoints need complementary patient reported outcomes","related_article_url":"https:\/\/blogs.bmj.com\/bmj\/2021\/09\/15\/surrogate-endpoints-need-complementary-patient-reported-outcomes\/"}],"the_bmj_article-journal_name":"The BMJ"},"head_tags":[{"tag":"title","content":"Raising the bar for using surrogate endpoints in drug regulation and health technology assessment | The BMJ"},{"tag":"meta","attributes":{"name":"robots","content":"max-image-preview:large"}},{"tag":"link","attributes":{"rel":"canonical","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/the-bmj-article\/raising-the-bar-for-using-surrogate-endpoints-in-drug-regulation-and-health-technology-assessment\/"}},{"tag":"meta","attributes":{"name":"generator","content":"All in One SEO (AIOSEO) 4.9.7.2"}},{"tag":"meta","attributes":{"property":"og:locale","content":"en_GB"}},{"tag":"meta","attributes":{"property":"og:site_name","content":"The BMJ | The BMJ: leading general medical journal. Research. Education. Comment"}},{"tag":"meta","attributes":{"property":"og:type","content":"article"}},{"tag":"meta","attributes":{"property":"og:title","content":"Raising the bar for using surrogate endpoints in drug regulation and health technology assessment | The BMJ"}},{"tag":"meta","attributes":{"property":"og:url","content":"https:\/\/bmj-chicken.bmj.com\/thebmj\/the-bmj-article\/raising-the-bar-for-using-surrogate-endpoints-in-drug-regulation-and-health-technology-assessment\/"}},{"tag":"meta","attributes":{"property":"article:published_time","content":"2021-09-16T00:01:10+00:00"}},{"tag":"meta","attributes":{"property":"article:modified_time","content":"2021-09-20T15:16:03+00:00"}},{"tag":"meta","attributes":{"name":"twitter:card","content":"summary"}},{"tag":"meta","attributes":{"name":"twitter:title","content":"Raising the bar for using surrogate endpoints in drug regulation and health technology assessment | The BMJ"}},{"tag":"link","attributes":{"rel":"alternate","type":"application\/rss+xml","title":"The BMJ \u00bb Feed","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/feed\/"}},{"tag":"link","attributes":{"rel":"alternate","type":"application\/rss+xml","title":"The BMJ \u00bb Comments Feed","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/comments\/feed\/"}},{"tag":"link","attributes":{"rel":"alternate","title":"oEmbed (JSON)","type":"application\/json+oembed","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/oembed\/1.0\/embed?url=https%3A%2F%2Fbmj-chicken.bmj.com%2Fthebmj%2Fthe-bmj-article%2Fraising-the-bar-for-using-surrogate-endpoints-in-drug-regulation-and-health-technology-assessment%2F"}},{"tag":"link","attributes":{"rel":"alternate","title":"oEmbed (XML)","type":"text\/xml+oembed","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/oembed\/1.0\/embed?url=https%3A%2F%2Fbmj-chicken.bmj.com%2Fthebmj%2Fthe-bmj-article%2Fraising-the-bar-for-using-surrogate-endpoints-in-drug-regulation-and-health-technology-assessment%2F&format=xml"}},{"tag":"link","attributes":{"rel":"https:\/\/api.w.org\/","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/"}},{"tag":"link","attributes":{"rel":"alternate","title":"JSON","type":"application\/json","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/the-bmj-article\/6124"}},{"tag":"link","attributes":{"rel":"EditURI","type":"application\/rsd+xml","title":"RSD","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/xmlrpc.php?rsd"}},{"tag":"meta","attributes":{"name":"generator","content":"WordPress 6.9.4"}},{"tag":"link","attributes":{"rel":"shortlink","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/?p=6124"}},{"tag":"meta","attributes":{"property":"og:locale","content":"en_GB"}},{"tag":"meta","attributes":{"property":"og:site_name","content":"The BMJ"}},{"tag":"meta","attributes":{"property":"og:title","content":"Raising the bar for using surrogate endpoints in drug regulation and health technology assessment"}},{"tag":"meta","attributes":{"property":"og:url","content":"https:\/\/bmj-chicken.bmj.com\/thebmj\/the-bmj-article\/raising-the-bar-for-using-surrogate-endpoints-in-drug-regulation-and-health-technology-assessment\/"}},{"tag":"meta","attributes":{"property":"og:type","content":"article"}},{"tag":"meta","attributes":{"property":"og:description","content":"The BMJ: leading general medical journal. Research. Education. Comment"}},{"tag":"meta","attributes":{"name":"twitter:title","content":"Raising the bar for using surrogate endpoints in drug regulation and health technology assessment"}},{"tag":"meta","attributes":{"name":"twitter:url","content":"https:\/\/bmj-chicken.bmj.com\/thebmj\/the-bmj-article\/raising-the-bar-for-using-surrogate-endpoints-in-drug-regulation-and-health-technology-assessment\/"}},{"tag":"meta","attributes":{"name":"twitter:description","content":"The BMJ: leading general medical journal. Research. Education. Comment"}},{"tag":"meta","attributes":{"name":"twitter:card","content":"summary_large_image"}}],"_links":{"self":[{"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/the-bmj-article\/6124","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/the-bmj-article"}],"about":[{"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/types\/the-bmj-article"}],"type":[{"embeddable":true,"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/types\/the-bmj-article"}],"wp:attachment":[{"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/media?parent=6124"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/categories?post=6124"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/tags?post=6124"},{"taxonomy":"article-type","embeddable":true,"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/content_type?post=6124"},{"taxonomy":"editorial-panel","embeddable":true,"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/editorial_panel?post=6124"},{"taxonomy":"channel-page","embeddable":true,"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/channel_page?post=6124"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}